Utah Medical Products Inc. Announces Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017
January 30, 2018 at 09:00 am EST
Share
Utah Medical Products Inc. announced audited consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported net sales of $10,201,000 compared to $8,852,000 a year ago. Operating income of $4,573,000 compared to $3,621,000 a year ago. Net loss was $2,522,000 or $0.674 per share compared to profit of $2,717,000 or $0.725 per share a year ago. Income before income tax was $4,578,000 against $2,717 for the last year.
For the year, the company reported net sales of $41,414,000 compared to $39,298,000 a year ago. Operating income of $19,011,000 compared to $16,187,000 a year ago. Net income was $8,505,000 or $2.276 per share compared to $12,128,000 or $3.220 per share a year ago. Income before income tax was $14,562,000 against $12,128 for the last year.
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.
UTAH MEDICAL PRODUCTS, INC. 
